Glucagon is a pancreatic hormone that plays a crucial role in regulating glucose and whole-body energy metabolism. In individuals with diabetes, the pancreatic alpha cells that produce glucagon are ...

Conclusions: Prevalence of obesity is increasing, and use of GLP-1 RAs as the preferred antiobesity medication has increased ...

With the rise of glucagon-like-peptide-1 receptor agonist medications (GLP-1RA) for obesity treatment, understanding diet quality can be a valuable tool for providing evidence-based nutrition guidance ...

Those with Type 1 diabetes (T1D) have higher glucagon levels right after eating than healthy individuals, but the reason why had not been determined. Using a novel glucagon isotope tracer, UAB ...

Indianapolis-based pharma giant Eli Lilly has announced the company now offers an Android version of its app, called Glucagon, which is designed to help caregivers and providers treat people with ...

When using glucagon-like peptide-1 drugs (GLP-1s) for weight loss or diabetes, you need to get comfortable with injecting the medication under your skin (subcutaneously). Typically, you will target ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic patients ...

In early 2025, around 4.9 million British adults — almost one in ten — are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Use of glucagon-like peptide-1 receptor agonists among ...

STOCKHOLM — A closed-loop insulin-delivery system, dubbed the 'artificial beta cell,' improved glucose control and reduced hypoglycemia compared with sensor-augmented insulin-pump therapy in patients ...

Please provide your email address to receive an email when new articles are posted on . Results showed 14 days may be the optimal cutoff for glucagon-like peptide-1 receptor agonists prior to hip or ...